SEC Comment Letter for Karyopharm Therapeutics (KPTI) — May 7, 2026
Karyopharm Therapeutics Inc.
Date: May 7, 2026 · CIK: 0001503802 · Accession: 0000000000-26-004695
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-295535
Letter
Re: Karyopharm Therapeutics Inc. Registration Statement on Form S-3 Filed May 4, 2026 File No. 333-295535 Dear Richard Paulson:
May 7, 2026
Richard Paulson President and Chief Executive Officer Karyopharm Therapeutics Inc. 85 Wells Avenue, 2nd Floor Newton, MA 02459
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Alan Campbell at 202-551-4224 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Craig Hilts
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> May 7, 2026 Richard Paulson President and Chief Executive Officer Karyopharm Therapeutics Inc. 85 Wells Avenue, 2nd Floor Newton, MA 02459 Re: Karyopharm Therapeutics Inc. Registration Statement on Form S-3 Filed May 4, 2026 File No. 333-295535 Dear Richard Paulson: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Alan Campbell at 202-551-4224 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Craig Hilts </TEXT> </DOCUMENT>